Innovative Cancer Technologies Adela specializes in developing cutting-edge methylation enrichment technologies for early cancer detection and minimal residual disease monitoring, making it a valuable partner for healthcare providers and laboratories seeking advanced diagnostic solutions.

Strong Funding and Growth With recent $48 million funding rounds led by prominent investors like OrbiMed and F-Prime Capital, Adela demonstrates solid financial backing and rapid growth potential, indicating significant market opportunities in oncology diagnostics.

Strategic Industry Presence Adela actively participates in leading clinical oncology events such as the ASCO Annual Meeting, showcasing validated research and establishing a reputation that can facilitate collaborations and commercialization efforts with hospitals and research institutions.

High-Impact Scientific Leadership Led by renowned scientist Dr. Daniel De Carvalho, who received prestigious awards, Adela benefits from cutting-edge scientific expertise that can enhance credibility and attract partnerships with biotech and pharma companies focused on cancer innovations.

Market Expansion Opportunities Adela’s focus on multi-cancer early detection and MRD monitoring positions it to serve a broad range of healthcare providers, laboratories, and research organizations seeking to adopt next-generation diagnostic platforms for improved patient outcomes.